JUNS JUPITER NEUROSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, JUPITER NEUROSCIENCES INC reported revenue of $24.2K, net income of −$2.27M and diluted EPS of −$4.08; for the fiscal year ended December 2025 revenue was $21.8K.
JUNS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $21.8K, gross profit $17.6K, operating income −$8.91M, net income −$8.64M (margin -39662.8%), EPS −$0.25
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$3.09M, net income −$2.44M (margin n/a), EPS −$0.08
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$3.87M, net income −$4.78M (margin n/a), EPS −$0.18
JUNS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $24.2K, net income −$2.27M, EPS −$4.08
- Quarter ended Mar 31, 2026: revenue $18.7K, net income −$2.06M, EPS −$0.06
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$2.58M, EPS $4.96
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.29M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.25M, EPS −$5.09
- Quarter ended Mar 31, 2025: revenue $0, net income −$1.53M, EPS −$0.05
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.53M, EPS −$0.05
- Quarter ended Sep 30, 2024: revenue n/a, net income −$591K, EPS −$0.02
- Quarter ended Jun 30, 2024: revenue n/a, net income $313K, EPS $0.01
- Quarter ended Mar 31, 2024: revenue n/a, net income −$634K, EPS −$0.02
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$430K, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.77M, EPS −$0.07
- Quarter ended Jun 30, 2023: revenue n/a, net income −$833K, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$1.75M, EPS n/a
JUNS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$5.41M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$3.91M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$481K, share buybacks n/a
JUNS balance sheet
- Jun 30, 2026: cash n/a, total assets $3.72M, total liabilities $4.08M, shareholders' equity −$366K
- Mar 31, 2026: cash n/a, total assets $3.95M, total liabilities $6.73M, shareholders' equity −$2.78M
- Dec 31, 2025: cash n/a, total assets $5.56M, total liabilities $7.40M, shareholders' equity −$1.83M
- Sep 30, 2025: cash n/a, total assets $2.58M, total liabilities $2.52M, shareholders' equity $57.4K
- Jun 30, 2025: cash n/a, total assets $3.97M, total liabilities $2.63M, shareholders' equity $1.34M
- Mar 31, 2025: cash n/a, total assets $4.96M, total liabilities $1.90M, shareholders' equity $3.06M
- Dec 31, 2024: cash n/a, total assets $6.20M, total liabilities $2.03M, shareholders' equity $4.17M
- Sep 30, 2024: cash n/a, total assets $85.5K, total liabilities $5.84M, shareholders' equity −$5.75M
What is JUNS's revenue?
JUPITER NEUROSCIENCES INC reported $21.8K of revenue for the fiscal year ended December 2025.
Is JUNS profitable?
No. JUPITER NEUROSCIENCES INC lost $9.20M over the last four quarters.
What is JUNS's EPS?
Diluted earnings per share over the last four quarters were $0.75; −$4.08 in the latest quarter.